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Introduction
Hepatocellular carcinoma (HCC) is the most common 
type of liver cancer. Cirrhosis is the most important risk 
factor for HCC while the main agents that lead to the 
development of HCC are hepatitis C virus (HCV) and 
hepatitis B virus (HBV) (Colombo et al., 1989). It is 
estimated about 350 million people are infected to chronic 
hepatitis B virus (HBV) throughout the world and is a 
major cause of liver cirrhosis and HCC (Wang et al., 2004; 
Gao et al., 2012). 
Some investigations in Iran show majority of HCC 
patients are positive for at least one of the HBV markers 
(Shamszad and Farzadegan, 1982; Merat et al., 2000) 
and a study in South of Iran demonstrated that the 
outstanding cause for HCC was hepatitis B (Hajiani et 
al., 2005). Other evaluations mentioned that prevention 
of infection with HBV decreases the risk of subsequent 
HCC (Pourhoseingholi et al., 2010; Wang et al., 2015). 
It is believed that HBV does not have a direct 
cytopathic effect on hepatocytes but some researchers have 
confirmed that in HBV-positive patients, the viral antigens 
that are presented in infected hepatocytes and targeted by 
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the cellular immune response and consequently, cause the 
liver damage. Studies have indicated that the immune 
response genes are the genetic component in chronic HBV 
infection. Human leucocyte antigen (HLA) class II genes 
and cytokine genes are associated with susceptibility to 
chronic HBV infection (Kummee et al., 2007).
Cytokines have a key role in the regulation of the 
immune response and defensive effect against viral 
infections. Polymorphisms in the cytokines genes 
determine the capacity of cytokine production among 
various individuals (Rapicetta et al., 2002; Lu et al., 
2015). Human interleukin 6 (IL6) is a multifunctional 
cytokine that interfere in the regulation of immune 
response (Kakumu et al., 1993; Galun et al., 2000). Studies 
represented, serum levels of IL6 is increased significantly 
in HBV patients (Malaguarnera et al., 1997; Song et al., 
2000). It has been shown that human interleukin 6 (IL6) 
facilitate hepatitis B virus infection in vivo and in vitro 
(Galun et al., 2000). 
There are three single nucleotide polymorphisms 
(SNP) at positions -597 G/A, -572 G/A and -174 G/C 
within the IL6 gene promoter region that prior studies 
indicated a cooperative influence of these SNPs on 
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regulation of IL6 transcription (Fishman et al., 1998; 
Terry et al., 2000). 
It is indicated that a polymorphism in the promoter 
region of IL-6 (position -174), would affect on the level of 
IL6 expression (Fishman et al., 1998). Based on previous 
reports, the polymorphism of this position is associated 
with some disease like diabetes (Fernandez-Real et al., 
2000; Hamid et al., 2005) Alzheimer (Capurso et al., 
2004) and multiple sclerosis (MS) (Shahbazi et al., 2010). 
Previous studies also confirmed the association of this 
polymorphism and HCV infection (Nattermann et al., 
2007; Cussigh et al., 2011). 
In case of the IL6-174 G/C promoter polymorphisms 
in susceptibility to hepatitis B virus (HBV) infection, there 
are deferent findings. Indeed, this relationship is not fully 
understood and was denied in some studies (Park et al., 
2003; Migita et al., 2005). Fabris C. et al in 2009 for the 
first time indicated a relationship between this position and 
the course of chronic HBV infection(Fabris et al., 2009). 
The aim of this study was to evaluate whether IL6-
174 G/C promoter polymorphisms are related to HBV 
infection resistance in an Iranian population in the north 
of Iran.
Materials and Methods
Study population
A total number of 665 Iranian people were classified 
in two different groups; HBV infected cases (n=297) 
with seropositive Hepatitis B surface antigen (HBsAg) 
and healthy controls (n=368). The HBV infected cases 
were collected from people whose HBV titer was tested 
by the Medical Cellular and Molecular Research Center 
(MCMRC) of Talghani Hospital (Gorgan, Iran). Healthy 
people who referred to Gorgan blood donation centers in 
Golestan province with HBS-Ag negative without history 
of autoimmune or inflammatory disorders were selected 
from the Northeast of Iran.
Demographic information
Average age of patients were 32±8.6 years and healthy 
individuals 36±8.43 years and sex ratio male to female in 
patients and controls was female: 25.6%, male: 74.4% and 
female: 44.48%, male: 55.52% respectively. For the above 
samples people with precluded environmental factors with 
the same sex and ethnicities were selected. 
Serological markers
HBsAg and antibodies to HBsAg (anti-HBs 
antigen) measurement were assessed by enzyme-linked 
immunosorbent assay (ELISA) using a commercial kit 
(Hepanostika, BioMérieux, Boxtel, Netherlands). 
HBV DNA extraction
Peripheral blood samples were gathered in EDTA tubes 
and genomic DNA was elicited using the QIAamp DNA 
Mini Kit (Qiagen, Hilden, Germany).
HBV load measurement
HBV viral load was measured by real-time polymerase 
chain reaction (RT-PCR) using the Artus Light Cycler 
HBV DNA Kit (Qiagen; Hilden, Germany) and Applied 
Biosystem 7300 Real Time PCR System (ABI).
Genomic DNA extraction 
Genomic DNA was extracted from 5 ml peripheral 
whole blood by modified standard protocol (Shahbazi 
et al., 2002). Briefly, red blood cells were lysed three 
times by lysis buffer. Then, SDS (10%), EDTA and 10 
μl proteinase K were added to the remained white cells. 
After incubation for 1 hour at 65 °C, a phenol/chloroform/
isoamylalcohol mix was added and centrifugation was 
performed after strongly mixing. The supernatant was 
separated and isopropanol and sodium acetate were 
added for precipitating the DNA. Visualized DNA was 
extracted after centrifugation and was dissolved in 
distilled water. Then, the concentration was determined 
by spectrophotometer at 260 nm (Techne, UK) and DNA 
samples were maintained in -20˚C.
Interleukin-6 genotyping
The SSP-PCR (sequence-specific  pr imer-
polymerase chain reaction) method was applied for 
genotyping (Mansoori et al., 2015); Each PCR reaction 
contained100-150 ng of DNA, 9.5 ml master mix 
containing 20 mm dNTP, 1X Ready load PCR buffer, 
12%Sucrose (Merck, Germany), one unit Taq DNA 
polymerase (GenetBio, Korea), 6 mm human growth 
hormone (HGH) primer as an internal control, and 30 
mm of each specific IL6 primer. The sequences of used 
primers are presented in Table 1.
The PCR reaction was carried out in a Thermal Cycler 
(Techne, UK), with the following program: 1min at 
95Cfollowedby10cyclesof 15 s at 95˚C, 50 s at 58˚C, 40 
s at 72˚C, followed by 20cycles of 20 s at 95˚C, 50 s at 
54˚Cand50sat72˚C, with 5min at 72˚C as final extension.
PCR product was submitted to electrophoresis using 
1.5% agarose gel (Merck, Germany) and stained by 
ethidium bromide. Using a gel documentation system 
(UVITEC, UK), DNA bands were visualized under the 
UV radiation.
Statistical analysis
Genotyped were tested for deviation from Hardy-
Weinberg equilibrium using web program (http://ihg.gsf.
de/cgi-bin/hw/hwa2.pl). Statistical analysis was done 
by the Statistical Program for Social Sciences (SPSS 
version 17.0) and the means of parametric variables 
were calculated. Data were presented as Mean±SD for 
parametric values and as percentages for non-parametric 
Table 1. Primer Sequences Used for the IL6 SSP 
Genotyping Method
Primer position Primer sequence
IL-6 (-174)C 5´-CCC CTA GTT GTG TCT TGC C-3´
IL-6 (-174)G 5´-CCC CTA GTT GTG TCT TGC G-3´
IL-6 (-174) 
Generic
5´-GCC TCA GAG ACA TCA CCA GTC 
C-3´
*HGH (sense) 5-GCCTTCCCAACCATTCCCTTA-3
HGH (antisense) 5-TCACGGATTTCTGTTGTGTTTC-3
*HGH=human growth hormone
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values. Alleles and genotype frequencies were calculated 
and compared by non-parametric tests followed by 
Fisher’s exact analysis using STATA v-8 (CA, US). 
P-values were determined, and those less than 0.05 were 
considered to be significant.
Results 
In the present study we evaluated position IL6-174 
SNP in 297 HBV patients and 368 control subjects using 
the SSP-PCR method. The study has been carried out at 
North-Eastern Iran. Each subject participated voluntarily, 
however they could cancel their participation at any time.
IL-6 Gene Promoter Polymorphisms Comparison between 
Patients and controls
Results showed that there was a significant difference 
in allele frequencies between the two groups. C allele 
were more frequent among healthy people compared 
with hepatitis B patients (OR=1.72, 95% CI=1.34-2.23, 
P=0.0000)
In addition, the G/G genotype was more frequent 
among patients (60.9 %) in comparison with control 
subjects (47.6%). The frequency of the C/G genotype 
was not significantly different between patients (34.3 %) 
and controls (39.7 %). Complementary data are presented 
in Table2.
Discussion
HCC distribution in the world is mostly due to spread 
of hepatitis B and hepatitis C virus. In Eastern Asia and 
sub-Saharan Africa, high frequency of HBV infection is 
the major risk factor for acquiring HCC (Parkin et al., 
2005; Fallot et al., 2012). 
To date, the association of polymorphisms of several 
genes and HBV infection has been assessed by several 
studies (Ben-Ari et al., 2003; Kim et al., 2003; Li et al., 
2012; Tayebi and Mohamadkhani, 2012; Jeng et al., 2014; 
Chanthra et al., 2015; Limothai et al., 2015; Nun-Anan 
et al., 2015). 
In the present study we aimed to verify the possible 
interference of IL6 -174 G/C polymorphism in HBV 
infection. Subsequently, we evaluated 297 HBV patients 
and 368 control individuals via SSP-PCR and gel 
electrophoresis methods. 
This simple PCR method is a cost effective method that 
apply three primer types for determining one of two alleles 
in each DNA sample (Table 1). HGH (human growth 
hormone) internal control has been used for eliminating 
liar responses in each PCR reaction. 
The human IL6 gene is located on chromosome 7p21 
and is composed of five exons and four introns. IL6 is 
a cytokine that plays a key role in the maturation and 
differentiation of the immune system (Galun et al., 2000; 
Rapicetta et al., 2002). 
As discussed above, Carlo Fabris and et al. demonstrated 
a relationship between IL6 -174 polymorphism and HBV 
infection (Fabris et al., 2009). This relationship was not 
detected by Migita K and Park BL in Far East Asian 
patients (Park et al., 2003; Migita et al., 2005). 
In this evaluation, a highly statistically significant 
difference in the frequency of the G/G polymorphism was 
observed between HBV patients and controls. Our study 
exhibited that the G allele and G/G genotype at the IL6 
-174 position had higher distribution among Iranian HBV 
patients (78.1% and 60.9 % respectively) in comparison to 
controls (67.4% and 47.6 % respectively) (Table 2). The 
majority of the patients (60.9 %) revealed the potential 
for producing G/G genotype compared with 47.6 % of the 
control group (p=0.000). 
In conclusion, these findings suggest that the IL6 G 
allele was strongly associated with susceptibility to HBV 
infection. 
Demographic information showed most of the subjects 
was male. This finding supports previous reports (Kumar 
et al., 2014). In general analysis, G/G genotype frequency 
in men is more prevalent while C/C genotype frequency 
in women is more common. According to G/G genotype 
frequency in patients can be said perhaps the men more 
than the women are susceptible to hepatitis (Table 3). 
Table 2. Frequency of the IL-6 Allele and Genotypes among Patients (N=297) and Controls (N=368).
Alleles and genotype Control n (%) Hepatitis n (%) OR* 95% CI* P-value*
C/C 47 (12.8 %) 14 (4.7 %) 1 - -
C/G 146 (39.7%) 102 (34.3 %) 2.35 1.2-4.8 0.0082
G/G 175 (47.6%) 181 (60.9 %) 3.47 1.8-7.1 0.00001
C/G + G/G  321(87.3%) 283(95.2%) - - -
C/G + C/C 193(52.5%) 116 (39%) - - -
C/G + G/G vs. C/C - - 2.96 1.56-5.94 0.0004
C/G + C/C vs. G/G  - - 0.58 0.42-0.80 0.0006
C 240 (32.6%) 130 (21.9%) 1 - -
G 496 (67.4%) 464 (78.1%) 1.72 1.34–2.23 0.00001
P values were determined by fisher’s exact test for allele frequencies, and by logistic regression test followed by Bonferroni’s correction for genotype 
frequencies
Table 3. L6 Sex Cross Tabulation in Study Participants
IL6 
Genotype
sex
TotalMen n (%) Women n (%)
CC 13 (21.3%) 48 (78.7%) 61(100.0%)
GG 209 (63.1%) 122 (36.9%) 331(100.0%)
CG 142 (60.7%) 92(39.3%) 234(100.0%)
Total 364 (58.1%) 262(41.9%) 626(100.0%)
Marzieh Attar et al
Asian Pacific Journal of Cancer Prevention, Vol 17, 20162398
Taken together, the results could be explained by 
divergences in the genetic background of the Iranian 
population. Although we did not study the IL6 serum 
levels in our population and it is still unclear, but it can 
be evaluated in the future. It is predicted that there is an 
association between genotype and expression level of 
IL6 gene.
It has been previously confirmed that substitution 
from the G to C allele at this position suppresses the 
transcription of IL6 (Shahbazi et al., 2002) which could 
explain how this SNP decreases the risk of development 
of disease.
In conclusion, the IL6 gene can be an important factor 
that affects the outcome of HBV infection and subsequent 
HCC and people with allele C at position -174 in the IL-6 
gene may be protected against HBV infection; 
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